Role of the tumor microenvironment in regulating apoptosis and cancer progression

Abstract

Apoptosis is a gene-directed program that is engaged to efficiently eliminate dysfunctional cells. Evasion of apoptosis may be an important gate to tumor initiation and therapy resistance. Like any other developmental program, apoptosis can be disrupted by several genetic aberrations driving malignant cells into an uncontrolled progression and survival. For its sustained growth, cancer develops in a complex environment, which provides survival signals and rescues malignant cells from apoptosis. Recent studies have clearly shown a wide interaction between tumor cells and their microenvironment, confirming the influence of the surrounding cells on tumor expansion and invasion. These non-malignant cells not only intensify tumor cells growth but also upgrade the process of metastasis. The strong crosstalk between malignant cells and a reactive microenvironment is mediated by soluble chemokines and cytokines, which act on tumor cells through surface receptors. Disturbing the microenvironment signaling might be an encouraging approach for patient's treatment. Therefore, the ultimate knowledge of "tumor-microenvironment" interactions facilitates the identification of novel therapeutic procedures that mobilize cancer cells from their supportive cells. This review focuses on cancer progression mediated by the dysfunction of apoptosis and by the fundamental relationship between tumor and reactive cells. New insights and valuable targets for cancer prevention and therapy are also presented.

Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression

“…It is well accepted that the microenvironment plays critical roles in driving tumorigenesis and dictating tumor progression (45,46). This is especially true for the IDH1 mutation, as one main feature of mutant IDH1 is the generation of the neometabolite D-2HG, which can be secreted into the extracellular compartment (6).…”

Synergistic combination of DT‐13 and Topotecan inhibits aerobic glycolysis in human gastric carcinoma BGC‐823 cells via NM IIA/EGFR/HK II axis

“…Renewed interest in the fact that cancer cells have to reprogramme their metabolism in order to proliferate or resist treatment. It must take into consideration that the ability of tumour cells to adapt their metabolism to the local microenvironment (low oxygen, low nutrients) . This variety of metabolic sources might be either a strength, resulting in infinite possibilities for adaptation and increased ability to resist chemotherapy‐induced death, or a weakness that could be targeted to kill cancer cells …”

Senescence marker protein 30 (SMP30) serves as a potential prognostic indicator in hepatocellular carcinoma

“…Among the 12 biological processes, apoptotic process1516 and biological adhesion1718 are related to the occurrence, development and metastasis of tumor. Previous studies19 have demonstrated that overexpression of SMP30 suppresses the expression of oncogenes c-myc and Haras, but encourages the expression of tumor suppressor gene p53 in rat hepatoma cell line H4-II-E.…”